Menu Search
Equities

AIM ImmunoTech Inc

HXB2:DUS

AIM ImmunoTech Inc

Actions
  • Price (EUR)0.222
  • Today's Change-0.006 / -2.63%
  • Shares traded--
  • 1 Year change-39.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 15:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AIM ImmunoTech Inc had net income fall 48.94% from a loss of 19.45m to a larger loss of 28.96m despite a 43.26% increase in revenues from 141.00k to 202.00k. An increase in the selling, general and administrative costs as a percentage of sales from 9,272.34% to 10,710.40% was a component in the falling net income despite rising revenues.
Gross margin71.14%
Net profit margin-13,952.74%
Operating margin-15,715.92%
Return on assets-113.70%
Return on equity-157.79%
Return on investment-149.16%
More ▼

Cash flow in USDView more

In 2023, cash reserves at AIM ImmunoTech Inc fell by 21.61m. Cash Flow from Financing totalled 485.00k or 240.10% of revenues. In addition the company used 21.27m for operations while cash used for investing totalled 832.00k.
Cash flow per share-0.5568
Price/Cash flow per share--
Book value per share0.1068
Tangible book value per share0.0632
More ▼

Balance sheet in USDView more

AIM ImmunoTech Inc has a Debt to Total Capital ratio of 30.18%.
Current ratio1.17
Quick ratio--
Total debt/total equity0.4322
Total debt/total capital0.3018
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.